Poster Session II - A250 REAL-WORLD EFFECTIVENESS, SAFETY, AND DOSE MODIFICATIONS OF UPADACITINIB IN PATIENTS WITH CROHN’S DISEASE: A CANADIAN MULTICENTER STUDY

Journal of the Canadian Association of Gastroenterology 2026 Open access

Read full text
Authors: Lisa M. A. van Lierop, R Dang, T Omeltchenko, M Adriaanse, Michal Gozdzik, Karen Ivy Kroeker, Brendan P. Halloran, K Wong, Farhad Peerani, J H Chow, Jeff McCurdy, Neeraj Narula
+5 more Jesse S. Siffledeen, Lillian Du, ThucNhi Tran Dang, Christopher Ma, Frank Hoentjen
DOI: 10.1093/jcag/gwaf042.250
Cited by: 0

Abstract

Abstract Background Upadacitinib (UPA) is widely used for the treatment of Crohn’s disease (CD) but data on clinical outcomes in daily practice remain scarce. Aims To assess the real-world effectiveness, safety, and dose modifications of UPA in patients with CD. Methods This multicenter retrospective cohort study included adults with CD initiating UPA at 7 Canadian centers (2019/10–2025/04). Patients were followed from treatment start until database lock (June 2025), discontinuation, or loss to follow-up (censored). The primary endpoint was corticosteroid-free clinical remission (CFCR; HBI

Fields of Study & Subjects

Inflammatory Bowel Disease Rheumatoid Arthritis Research and Therapies Pregnancy and Medication Impact

Publication details

Journal / source
Journal of the Canadian Association of Gastroenterology
Volume
9
Issue
Supplement_1
Publication date
1 February 2026
Language
EN